# Humacyte Plans sBLA Submission for Symvess in Hemodialysis Access

- URL: https://stocks.freetheai.org/news/humacyte-plans-sbla-submission-for-symvess-in-hemodialysis-access-88cd7b
- Published: 2026-10-12T12:00:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:HUMA](https://stocks.freetheai.org/symbols/NASDAQ-HUMA)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Humacyte, Inc. (HUMA) plans to submit a supplemental Biologics License Application this quarter to expand the approval of its bioengineered vessel, Symvess, for arteriovenous access in hemodialysis patients. The company will also deliver a late-breaking oral presentation covering interim Phase 3 V012 trial data at ASN Kidney Week 2026. Shares of Humacyte fell 9.35% to $0.4053 during today's trading session.

Symvess is currently approved for vascular trauma treatment. Extending its indication to hemodialysis access would broaden its market reach into end-stage kidney disease treatment. The ongoing trial specifically focuses on female patients with end-stage kidney disease, a population that frequently encounters higher rates of fistula failure. The regulatory submission will incorporate data from two previous Phase 3 clinical trials alongside the latest Phase 3 findings.

Investors will look for the upcoming data presentation at ASN Kidney Week 2026 to evaluate the interim Phase 3 results. Additionally, a timely submission and potential acceptance of the regulatory filing by health authorities will determine the timeline for expanding the drug's commercial availability.

## Key points

- Humacyte, Inc. expects to submit a supplemental Biologics License Application this quarter for AV access in hemodialysis.
- Interim Phase 3 V012 trial results for ATEV will be presented in a late-breaking oral session at ASN Kidney Week 2026.
- The Phase 3 trial targets women with end-stage kidney disease, a subgroup prone to higher rates of fistula failure.
- Symvess is currently approved for treating vascular trauma.
- Shares of Humacyte dropped 9.35% to $0.4053 on the day of the announcement.

## Questions and answers

### What is Humacyte planning to submit this quarter?

Humacyte, Inc. expects to submit a supplemental Biologics License Application to expand its vessel product, Symvess, for use in arteriovenous access for hemodialysis.

### Where will Humacyte present its Phase 3 V012 trial data?

Interim Phase 3 V012 results for ATEV will be presented during a late-breaking oral presentation at ASN Kidney Week 2026.

### What is Symvess currently approved for?

Symvess, also known as ATEV, is currently approved for the treatment of vascular trauma.